Literature DB >> 15156239

Panic Attacks During Escalation of Mirtazapine.

Timothy R. Berigan1.   

Abstract

Entities:  

Year:  2003        PMID： 15156239      PMCID： PMC353045          DOI： 10.4088/pcc.v05n0208

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN： 1523-5998


× No keyword cloud information.
  9 in total

1.  Panic attacks during discontinuation of mirtazepine.

Authors:  J Klesmer; A Sarcevic; V Fomari
Journal:  Can J Psychiatry       Date:  2000-08       Impact factor: 4.356

Review 2.  Tolerability and safety aspects of mirtazapine.

Authors:  David J Nutt
Journal:  Hum Psychopharmacol       Date:  2002-06       Impact factor: 1.672

3.  Mirtazapine in the treatment of panic disorder.

Authors:  Vladimir Carli; Marco Sarchiapone; Giovanni Camardese; Luisa Romano; Sergio DeRisio
Journal:  Arch Gen Psychiatry       Date:  2002-07

4.  The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period.

Authors:  M L Boshuisen; B R Slaap; E D Vester-Blokland; J A den Boer
Journal:  Int Clin Psychopharmacol       Date:  2001-11       Impact factor: 1.659

5.  Mirtazapine versus fluoxetine in the treatment of panic disorder.

Authors:  L Ribeiro; J V Busnello; M Kauer-Sant'Anna; M Madruga; J Quevedo; E A Busnello; F Kapczinski
Journal:  Braz J Med Biol Res       Date:  2001-10       Impact factor: 2.590

Review 6.  Care of depressed patients with anxiety symptoms.

Authors:  D J Nutt
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

7.  Clinical experience with mirtazapine in the treatment of panic disorder.

Authors:  L L Carpenter; Z Leon; S Yasmin; L H Price
Journal:  Ann Clin Psychiatry       Date:  1999-06       Impact factor: 1.567

Review 8.  A review of the pharmacological and clinical profile of mirtazapine.

Authors:  S A Anttila; E V Leinonen
Journal:  CNS Drug Rev       Date:  2001

9.  Mirtazapine in the treatment of panic disorder: an open-label trial.

Authors:  M Sarchiapone; M Amore; S De Risio; V Carli; V Faia; F Poterzio; C Balista; G Camardese; G Ferrari
Journal:  Int Clin Psychopharmacol       Date:  2003-01       Impact factor: 1.659
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.